Poseida Therapeutics appoints corporate affairs lead
Poseida Therapeutics has announced the appointment of Marcy Graham as vice president of corporate affairs, responsible for investor relations, corporate communications and other functions within the company.
Graham started in the first week of October and reports directly into the company’s CFO. This is the first time Poseida Therapeutics has had an in-house IR representative.
‘Due to the innovation of its science, the company is growing and has an increasing need for a professional with experience working with a variety of external audiences, as well as someone who can work with employees and management to plan communications approaches and train new executives,’ Graham says.
Eric Ostertag, chief executive of Poseida, praises Graham’s depth of experience in the sector. ‘With her exceptional track record at fast-growing life science companies, Marcy is a key addition to our team as we enter our next stage of corporate growth,’ he says in a press release.
Graham recently served as vice president of investor relations and corporate communications at Mirati Therapeutics and aTyr Pharma, working on the latter’s IPO in 2015. She has also overseen investor relations and corporate communications programs at Ambit Biosciences, Sequenom and Genoptix.